Neurofilament light chain levels in cerebrospinal fluid as a sensitive biomarker for cerebral adrenoleukodystrophy.
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
17
05
2023
received:
24
04
2023
accepted:
19
05
2023
medline:
19
7
2023
pubmed:
1
6
2023
entrez:
1
6
2023
Statut:
ppublish
Résumé
Adrenoleukodystrophy (ALD) has a poor prognosis when it progresses to the cerebral form (CALD). The aim of this study is to investigate whether cerebrospinal fluid (CSF) neurofilament light chain (cNfL) is a sensitive biomarker for detecting CALD and assessing response to hematopoietic stem cell transplantation (HSCT). We conducted a cross-sectional study of 41 male ALD patients. The cNfL levels in patients with the cerebral form of ALD (CALD) or the cerebello-brainstem form of ALD were compared with those in patients with adrenomyeloneuropathy (AMN). The correlation between cNfL levels and MRI-based Loes severity scores was investigated. A longitudinal analysis was performed on patients who underwent multiple CSF examinations. The cNfL levels in 22 patients with CALD were significantly higher than those in 14 patients with AMN (median, 5545 vs. 1490 pg/mL; p < 0.001). The cutoff cNfL level of 1930 pg/mL showed good sensitivity (95.5%) and specificity (85.7%) for distinguishing CALD from AMN. The cNfL levels were positively correlated with Loes scores (p < 0.001). The cNfL levels in three AMN patients who later converted to CALD increased above the cutoff level during the conversion period, while the cNfL levels in four patients who remained in AMN were consistently below the cutoff. In 10 ALD patients who underwent HSCT, their cNfL levels decreased 3-24 months after HSCT. Two patients whose cNfL increased after HSCT showed deterioration in cognitive functions. The cNfL level is useful for evaluating the disease activities of ALD and the response to HSCT.
Identifiants
pubmed: 37259474
doi: 10.1002/acn3.51818
pmc: PMC10351652
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1230-1238Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Neurology. 2020 Jun 16;94(24):e2499-e2507
pubmed: 32482842
Brain Dev. 2005 Aug;27(5):353-7
pubmed: 16023551
N Engl J Med. 1990 Jun 28;322(26):1860-6
pubmed: 2348839
J Hum Genet. 2002;47(11):590-3
pubmed: 12436195
AJNR Am J Neuroradiol. 1994 Oct;15(9):1761-6
pubmed: 7847225
Nat Commun. 2021 Mar 22;12(1):1816
pubmed: 33753741
Ann Clin Transl Neurol. 2020 Nov;7(11):2127-2136
pubmed: 33047897
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
Lancet. 2000 Aug 26;356(9231):713-8
pubmed: 11085690
Neurology. 2017 Nov 28;89(22):2230-2237
pubmed: 29079686
AJNR Am J Neuroradiol. 2016 Feb;37(2):367-72
pubmed: 26427835
Nature. 1993 Feb 25;361(6414):726-30
pubmed: 8441467
Brain Commun. 2020 Jan 14;2(1):fcz048
pubmed: 32954314
Arch Neurol. 1999 Mar;56(3):295-300
pubmed: 10190819
Neurology. 1984 Nov;34(11):1410-7
pubmed: 6387532
Front Neurosci. 2021 Apr 06;15:642384
pubmed: 33889068
Blood. 2004 Aug 1;104(3):881-8
pubmed: 15073029
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Lancet Neurol. 2007 Aug;6(8):687-92
pubmed: 17618834
Nat Clin Pract Neurol. 2007 Mar;3(3):140-51
pubmed: 17342190